– USA, CA – Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Dr. Bonnie Bassler, Ph.D., and Carin Canale-Theakston to its board of directors.
“We are pleased to welcome Dr. Bassler and Ms. Canale-Theakston to our board of directors,” said CEO, Dr. Jeffrey Stein.
He added: “We look forward to leveraging Dr. Bassler’s expertise in molecular biology and vast experience serving on boards across academia and the biotech industry and Ms. Canale-Theakston’s 25+ years of experience spearheading complex business and communication strategies for life science companies. Their combined expertise will be of tremendous value as we advance our novel antifungal, rezafungin, currently in pivotal Phase 3 trials, towards filing, and our antiviral conjugate influenza program to IND filing.”
About Dr. Bonnie Bassler
Dr. Bassler, an internationally-renowned molecular biologist, is a Howard Hughes Medical Institute Investigator and the chair of the department of molecular biology and the Squibb Professor in molecular biology at Princeton University. She currently serves as a board member of Regeneron, Kaleido Biosciences, and Royalty Pharma. Dr. Bassler has previously served as a board member of Sanofi, the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology, where she also served as the president. Dr. Bassler’s scientific honors include a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. She holds a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.
About Carin Canale-Theakston
Ms. Canale-Theakston, a seasoned life science executive, is the CEO and founder of Canale Communications, a life science communications firm. Over the course of her career, she has led corporate strategy and corporate communications for more than 300 life science companies of varying sizes and stages. Ms. Canale-Theakston serves as vice-chair of the board of directors for Biocom California, and co-chairs both the Biocom Capital Development Committee and the board’s nominating and governance committee. She has received a multitude of awards, including the E&Y Entrepreneur of the Year award for 2019, California Assemblywoman Toni G. Atkins “Woman of the Year” for the 78th assembly district and San Diego 500 list of influential business leaders in life sciences from 2016-2020. Ms. Canale-Theakston previously served as president of the life sciences division of international public relations firm, Porter Novelli. She holds a B.S. in marketing & communications from the University of Tulsa.
About Rezafungin
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.
For more information : https://www.cidara.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
